GoingToMeet

The humoral immune response is an exquisite biosensor of novel proteins expressed by tumor cells. Panels of tumor antigens could provide a sensitive and specific multianalyte immunoassay for the presymptomatic of cancer by measuring antitumor autoantibodies in serum. The development of early detection tests for cancers has previously depended on single biomarker molecules. Using a high-throughput cloning method, a panel of epitopes/antigens that react with autoantibodies to tumor proteins in the serum of patients with cancer have been isolated. The binding properties of these serum antitumor antibodies on microarrays and advanced bioinformatics tools led to a panel of diagnostic antigens. The sequences that were identified using high-throughput phage display cloning technology have led to the discovery of novel disease-related proteins. There are numerous advantages of employing serum antibodies as the analytes, not the least of which is the ability to readily adapt these assays to standard clinical immunoassay platforms.